Label Image (Lbl500904255)
Losartan Potassium
Product Images NDC 50090-4255
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-4255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Spl Image1 Structure1)
Figure 1 (Spl Image2 Figure1)
This appears to be a comparison between two medication treatments, Atenolol and Losartan Potassium, in terms of their effect on the primary endpoint for a study period of 66 months. The adjusted risk reduction for Losartan Potassium was 13% with a p-value of 0.021. The text is accompanied by a graph displaying the study month intervals.*
Figure 2 (Spl Image3 Figure2)
This is a comparison study between two medications Atenolol and Losartan Potassium. The Adjusted Risk Reduction is 25% with a p-value of 0.001. The percentage of patients with fatal/non-fatal stroke is given over time intervals from 6 to 66 months.*
Figure 3 (Spl Image4 Figure3)
This is a table showing the results of a study comparing the efficacy of Losartan Potassium and Atenolol in reducing stroke risk in different subgroups of patients. The primary endpoint of the study was the composite of fatal and non-fatal stroke. The table presents the number of events, rates, hazard ratios, and confidence intervals for each subgroup, including age, gender, race, hypertension, diabetes, and history of cardiovascular disease. The symbols in the table are proportional to sample size, and the results show that Losartan Potassium is favored over Atenolol in reducing stroke risk in some subgroups. The analysis was adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 (Spl Image5 Figure4)
This is a graph showing the percentage of patients with an event for Losartan Potassium and Placebo over 48 months. It also indicates a risk reduction of 16.1% with a p-value of 0.022.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
